AVITA Medical Clears RECELL GO for Launch in Australia and New Zealand Markets
AVITA Medical secures regulatory clearance for RECELL GO in Australia and New Zealand
AVITA Medical has received Therapeutic Goods Administration certification in Australia and Medsafe WAND listing in New Zealand for RECELL GO, its next-generation system that automates preparation of RECELL Spray-On Skin for burn and trauma wounds. The regulatory clearances enable commercialisation across both markets, with exclusive distribution partner Revolution Surgical Pty Ltd expecting to initiate commercial launch within the coming weeks.
The approvals expand RECELL GO’s geographic footprint alongside existing regulatory clearances in the United States, Europe, and the United Kingdom. The system represents AVITA Medical’s evolution from manual preparation processes to an automated, standardised platform designed to reduce clinical complexity whilst optimising cell yield and viability.
For investors, the TGA certification and WAND listing remove a critical commercialisation barrier in two developed markets. Revenue generation can now commence once Revolution Surgical initiates the commercial launch, activating a pathway through an established distribution partner with existing healthcare provider relationships.
When big ASX news breaks, our subscribers know first
What is RECELL GO and how does it work?
RECELL GO comprises two components: a reusable, AC-powered RECELL Processing Device and a single-use RECELL Preparation Kit. One preparation kit can treat wounds up to 1,920 cm².
The system automates a process that historically required manual preparation in Australia. RECELL GO precisely regulates enzyme incubation times and processing conditions, optimising cell yield and viability whilst reducing operator variability.
The key advantages over manual preparation include:
- Standardised enzyme incubation timing
- Optimised cell yield and viability
- Reduced training requirements
- Lower operating room complexity
The underlying RECELL mechanism uses a small sample of the patient’s own healthy skin to prepare a cell suspension that is sprayed onto wounds. This approach promotes faster healing, reduces the need for large skin grafts, lowers donor-site pain and scarring, and shortens hospital stays.
The automation and standardisation address adoption barriers in clinical settings. Reducing complexity may accelerate uptake among healthcare providers who found manual preparation prohibitive, translating to faster market penetration and revenue ramp.
Professor Fiona Wood endorses the evolution of Australian-developed technology
Professor Fiona Wood, Director of the Burns Service of Western Australia and Director of the Burn Injury Research Unit at the University of Western Australia, originally developed the RECELL technology in Australia. She was recently awarded the Lifetime Achievement Award by the American Burn Association at the ABA’s 2026 Annual Meeting.
Professor Fiona Wood
“RECELL GO represents the evolution of a technology we developed in Australia, building on our original approach by eliminating manual preparation steps and reducing the burden on clinical teams. Its certification is significant in expanding RECELL access for burn and trauma patients across Australia and New Zealand.”
Endorsement from the technology’s original developer and a globally recognised burns expert provides clinical credibility that can support adoption discussions with hospitals and clinicians. This validation from a respected authority in burn treatment may accelerate acceptance within the Australian and New Zealand healthcare systems.
Management perspective on market expansion
Cary Vance, Interim Chief Executive Officer of AVITA Medical, emphasised the significance of the regulatory clearances for expanding RECELL access.
Cary Vance, Interim CEO
“The TGA certification and WAND listing of RECELL GO represents an important step in expanding access to RECELL. With RECELL GO, we are bringing greater standardization and efficiency to the preparation process, and together with our partner Revolution Surgical, we look forward to supporting adoption across Australia and New Zealand.”
RECELL GO’s global regulatory footprint
The Australian and New Zealand clearances complete another component of AVITA Medical’s broader international rollout, positioning the company to pursue revenue growth across multiple geographies simultaneously.
| Market | Regulatory Status | Product |
|---|---|---|
| United States | FDA approved | RECELL, RECELL GO |
| Europe | CE-marked | RECELL, RECELL GO |
| United Kingdom | CE-marked | RECELL, RECELL GO |
| Australia | TGA certified | RECELL, RECELL GO |
| New Zealand | Medsafe WAND listed | RECELL, RECELL GO |
| Japan | PMDA approved | RECELL |
RECELL GO now holds approval across five major developed markets (United States, Europe, United Kingdom, Australia, New Zealand). Japan remains a RECELL-only market for now, with RECELL GO not yet approved by the Pharmaceuticals and Medical Devices Agency.
The geographic diversification reduces single-market concentration risk whilst providing multiple revenue streams. Each market operates through different commercialisation models, with Revolution Surgical handling Australia and New Zealand distribution.
The next major ASX story will hit our subscribers first
What this means for investors
The regulatory clearances remove a commercialisation barrier in two markets that collectively represent an established patient population for burn and trauma treatment. AVITA Medical operates through Revolution Surgical in Australia and New Zealand rather than direct sales, leveraging existing relationships and infrastructure to reduce market entry costs and accelerate adoption.
The near-term catalyst centres on the commercial launch expected within weeks. This timing provides visibility on when revenue generation can commence, subject to hospital purchasing decisions and clinician adoption rates.
AVITA Medical’s broader product portfolio includes RECELL, Cohealyx (a collagen-based dermal matrix), and PermeaDerm (a biosynthetic wound matrix) in the United States. The Australia and New Zealand clearances focus specifically on RECELL GO for burn and trauma wounds.
Key investor takeaways:
- Regulatory hurdle cleared for Australia and New Zealand
- Commercial launch imminent via established distribution partner
- RECELL GO’s automation may accelerate clinical adoption versus manual preparation
- Adds to global footprint alongside United States, Europe, United Kingdom, and Japan
Ready to Learn More About AVITA Medical’s RECELL GO Technology?
The TGA certification and WAND listing unlock commercial opportunities across Australia and New Zealand, with Revolution Surgical expected to commence the launch within weeks. This regulatory milestone expands RECELL GO’s footprint across five major developed markets, positioning AVITA Medical for accelerated adoption through automated preparation technology.
For comprehensive company updates and detailed investment analysis, visit the AVITA Medical investor centre to track commercialisation progress and strategic developments. Access full announcements, financial reports, and market insights to evaluate AVITA Medical’s position in the burn and trauma treatment sector.